Active GLP-1, incretin multi-agonist and amylin trials

RecordSTO-AMY20EM2RN-W8Q9RJFE4W-N91N7E

600

Global · as of 27 Sep 2026

Active GLP-1, incretin multi-agonist and amylin trials worldwide was 600 (ClinicalTrials.gov, published 27 September 2026).

Original source

Publisher: ClinicalTrials.gov
Authority tier: T1 Official
Report: ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27
Locator: totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.
Retrieved: 27 Sep 2026
Status: Verified

What the source says

{"totalCount":600,"studies":[
ClinicalTrials.gov (U.S. National Library of Medicine), ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27, totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.

Checked: the figure 600 is stated in this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

APA

ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E

Other formats: MLA, Chicago, BibTeX

MLA: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27." 2026, https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Accessed 27 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E.
Chicago: ClinicalTrials.gov (U.S. National Library of Medicine). "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27." 2026. https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Accessed September 27, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E.
BibTeX: @misc{clinicaltrialsgo2026ctgovn91n7e, author = {{ClinicalTrials.gov (U.S. National Library of Medicine)}}, title = {ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E}, note = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide\%20OR\%20tirzepatide\%20OR\%20retatrutide\%20OR\%20orforglipron\%20OR\%20survodutide\%20OR\%20cagrilintide\%20OR\%20CagriSema\%20OR\%20mazdutide\%20OR\%20liraglutide\%20OR\%20dulaglutide\%20OR\%20exenatide\%20OR\%20ecnoglutide\%20OR\%20danuglipron\%20OR\%20pemvidutide\%20OR\%20amycretin\%20OR\%20efinopegdutide\%20OR\%20MariTide\%20OR\%20maridebart\%20OR\%20petrelintide\%20OR\%20\%22GLP-1\%20receptor\%20agonist\%22\%20OR\%20LY3437943\%20OR\%20LY3502970\%20OR\%20\%22BI\%20456906\%22\%20OR\%20LY3298176\%20OR\%20IBI362\%20OR\%20\%22AMG\%20133\%22\%20OR\%20\%22NNC0487-0111\%22\&filter.advanced=AREA\%5BStudyType\%5DINTERVENTIONAL\&filter.overallStatus=RECRUITING\%2CNOT\_YET\_RECRUITING\%2CACTIVE\_NOT\_RECRUITING\%2CENROLLING\_BY\_INVITATION\&countTotal=true\&pageSize=1\&fields=NCTId. Accessed September 27, 2026.} }

Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Primary source

Publisher: ClinicalTrials.gov (U.S. National Library of Medicine) · homepage ↗
Authority tier: Tier 1 · Multilateral Official
Report: ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27
Type: Dataset
Published: —
Locator: totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.
Retrieved: 27 September 2026
Link status: Reachable (HTTP 200)
Report licence: Public domain

Verification

Status: Verified
Review protocol: pipeline:ctgov-api-totalcount-verified
Checked on: 27 September 2026
Last revision: 27 September 2026
Permanent URL: /stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E

Active GLP-1, incretin multi-agonist and amylin trials

What the source says

Cite this figure

Provenance and verification

Primary source

Verification

Related

This figure in context

Cited in

Go further